Twist Bioscience Agrees to $17.1 Million Investor Settlement (1)

Twist Bioscience Corp. and two executives reached a nearly $17.1 million settlement to resolve allegations they misled investors about the company’s synthetic DNA quality and automated manufacturing.

The proposed settlement class would include investors who acquired Twist stock in a 2020 offering or from Dec. 20, 2018, through Nov. 15, 2022, according to a motion seeking the deal’s preliminary approval filed Thursday.

If approved in the US District Court for the Northern District of California, the accord would end more than three years of litigation started in the wake of a November 2022 short-seller report.

Twist’s stock price plummeted almost ...